Medikit to expand medical-device production capacity at Hyuga Second Plant
Pharma & medicalMiyazaki
Medikit plans to invest in medical-device production equipment at Togo Medikit's Hyuga Second Plant in Hyuga, Miyazaki. The project is scheduled to begin in December 2024 and be completed in January 2027, increasing component production capacity.
Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.
JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.
Lion has approved construction of a new pharmaceutical plant through its wholly owned Vietnamese subsidiary Merap Lion. The facility will produce prescription and over-the-counter solid-dose medicines, including tablets and granules, with operations planned to begin in the second half of 2030.
Tsumura will build a new QC building and hazardous-materials warehouse at its Ibaraki Plant in Ami, Ibaraki, to strengthen quality-testing capacity and business continuity for its kampo pharmaceutical products. Construction costs approximately ¥7 billion, designed and built by Kajima Corporation, with completion planned for mid-April 2028.
HOYA Lens Brazil plans to rationalize and expand manufacturing equipment for healthcare-related products at its Rio de Janeiro facility. The project is funded internally, with a total planned investment of JPY 1.027 billion; no construction schedule or capacity increase is disclosed.